RBC Capital Maintains Outperform on Johnson & Johnson, Sets Target at $290
RBC Capital reaffirmed its Outperform rating on Johnson & Johnson's stock, setting a price target of $290.00. This target represents a potential upside of 14.7% from the stock's closing price of $252.93 on October 5. The analyst note highlighted strong performance within the company's Innovative Medicines segment.